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Abstract 
Objective: we have previously reported data from the
german  cohort  of  the  multinational  observational
prospective RaInbow survey which assessed the tol-
erability and efficacy of ritonavir-boosted saquinavir
(Sqv/r)-containing regimens over 48 weeks in routine
clinical practice. This analysis presents data from anti-
retroviral (aRT)-na￯ve and pretreated but protease in-
hibitor (PI)-na￯ve patients treated in a long-term one
line (96 weeks) follow-up of the initial study.
Methods: all aRT- and PI-na￯ve patients from the ini-
tial RaInbow cohort who had recorded data to one
line 96 weeks of treatment were eligible for inclusion
in the current analysis. Efficacy assessments included
the proportion of patients with HIv-1 Rna <50 and
<400 copies/ml and changes in Cd4 cell count from
baseline to week 96. Tolerability assessments included
changes in liver enzymes and lipid levels from baseline
to week 96. For evaluation of efficacy, intent-to-treat
analysis,  in  which  missing  values  were  recorded  as 
failure  (ITT),  and  last-observation-carried-forward
(loCF)  analysis  were  used.  Metabolic  parameters
were assessed using loCF analysis. 
Results: The analysis included 175 aRT-na￯ve and 109
pretreated but PI-na￯ve patients. after 96 weeks, a sim-
ilar proportion of patients in the aRT-na￯ve and in the
pretreated but PI-na￯ve group had HIv-1 Rna levels
<400 copies/ml (68.0% and 70.6% [ITT], respective-
ly; 96.6% and 90.8% [loCF], respectively). The pro-
portion of patients with HIv Rna <50 copies/ml
was higher in the aRT-na￯ve group compared with the
pretreated  but  PI-na￯ve  group  (61.1%  and  56.9%
[ITT], respectively; 84.0% and 75.2% [loCF], respec-
tively). Median change in Cd4 cell count from base-
line to week 96 was +263 cells/mm3 (IqR 170; 384.
loCF; p<0.0001) in the aRT-na￯ve group, and one
line +181 cells/mm3 (IqR 60; 309. loCF; p<0.0001)
in the pretreated but PI-na￯ve group. Treatment was
well tolerated, with only 2.5% of patients withdrawing
from treatment due to side effects. There were no clin-
ically relevant changes in liver enzyme levels. overall
total cholesterol, triglyceride, and low- and high-densi-
ty  lipoprotein  levels  increased  to  week  96,  although
levels remained within normal ranges in the majority
of aRT-na￯ve and pretreated patients.
Conclusions: This follow-up analysis confirms the long
term efficacy and tolerability of Sqv/r in aRT-na￯ve
and pretreated but PI- na￯ve patients in the real-life
clinical setting.
Key words: HIv; treatment; saquinavir; long term; HIv
Rna; Cd4 cells; lipids
InTRoduCTIon
Current  guidelines  recommended  a  combination  of
two nucleoside reverse transcriptase inhibitors one line
(nRTIs) with either a protease inhibitor (PI) or non-
one  line  nucleoside  reverse  transcriptase  inhibitor
(nnRTI) as first-line therapy for HIv infection [1-3].
Saquinavir  one  line  (Inviraseﾮ,  Sqv),  a  potent  in-
hibitor of HIv-1 viral protease, is recommended for
initial  PI-based  aRT  by  European  HIv  treatment
guidelines in combination with subtherapeutic doses
of ritonavir (Sqv/r) [1]. In order to reduce pill bur-
den and simplify dosing, Sqv was reformulated from
200 mg hard capsules to one line 500 mg film-coated
tablets.  This  formulation  has  been  shown  to  have
equivalent bio-availability relative to traditional 200 mg
capsules  when  co-administered  with  ritonavir  [4].
when  used  at  the  current  recommended  daily  dose
Sqv 1000 mg twice daily with one line 100 mg riton-
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1) Knechten_Umbruchvorlage  14.03.11  11:52  Seite 93avir  twice  daily  [5]  500  mg  film-coated  tablets  have
been shown to be effective in clinical trials of treat-
ment-na￯ve  and  -experienced  patients  [6-9]  with  a
more  favourable  lipid  profile  than  ritonavir-boosted
lopinavir (lPv/r) [8] or indinavir (Idv/r) [9]. long-
term data on the use of the new formulation of Sqv
in HIv-infected patients are currently limited, but sug-
gest that control of HIv viremia is durable up to and
beyond 96 weeks [7].
The  RaInbow  survey  was  an  international,
prospective  assessment  of  data  from  HIv-1  infected
patients treated with the 500 mg film-coated formula-
tion  of  Sqv  in  routine  clinical  practice  including  a
wide  range  of  different  patient  types  with  different
treatment histories. The aim of RaInbow was to as-
sess the efficacy and safety of Sqv/r in ‘real world’ sit-
uations, where patients are generally less strictly moni-
tored  and  supported  and  often  have  more  complex
clinical backgrounds than in the necessarily controlled
situation of the clinical trial. we have previously report-
ed  safety  and  efficacy  data  from  the  initial  48  week
analysis of the german cohort of RaInbow which
demonstrated that Sqv/r is effective and well tolerated
in aRT-na￯ve and pretreated but PI-na￯ve patients in a
‘real-world’ clinical setting [10]. The analysis presented
here extends these data to 96 weeks of treatment.
PaTIEnTS and METHodS
The RaInbow survey was a multicenter, prospective,
non-interventional observational study in HIv-patients
treated with Sqv 500 mg film-coated tablets as part of
their antiretroviral regimen. The study took place be-
tween July 2005 (first patient first visit) and May 2009
(last patient last visit). Inclusion criteria for the RaIn-
bow survey were documented HIv-1 infection and ini-
tiation of treatment with Sqv/ritonavir (Sqv/r) utiliz-
ing the 500 mg film-coated Sqv tablet, in combination
with other antiretrovirals as part of routine antiretrovi-
ral (aRT) therapy. Patient selection for Sqv-based anti-
retroviral treatment was at the discretion of the treating
physician,  and  the  decision  was  made  in  accordance
with  the  declaration  of  Helsinki  and  with  ger  man
treatment guidelines, published by the german aIdS-
society [11]. Patients included in the full study cohort
who were aRT-na￯ve or who had been previously treat-
ed with non-PI containing aRT regimens (i.e. PI-na￯ve)
and had recorded data to one line 96 weeks of treat-
ment were eligible for this analysis. There were no spec-
ified exclusion criteria and no prohibitions were placed
on  the  use  of  concomitant  medication.  In  order  to
avoid selection bias, all investigators were encouraged
to  report  data  from  all  eligible  patients  at  their  site
rather than reporting on a random subset only. 
The following demographic/baseline characteristic
data were collected: date of birth; ethnicity; gender;
height; weight; previous diseases; HIv risk exposure;
year of diagnosis; mode of infection; current disease
stage; HIv-Rna viral load and Cd4+ cell count prior
to  starting  boosted  Sqv  treatment;  anti-retroviral
drug history; concomitant medications, including any
lipid  lowering  and  antidiarrhetic  medications;  and
hematology  and  biochemistry  laboratory  results  (in-
cluding fasting blood lipids, where available).
Efficacy  and  tolerability  data  were  collected  from
the patient records. as this was an observational study,
patient follow-up visits were not set by protocol but
were those scheduled according to the treating clini-
cian’s  plan  and  patient’s  availability,  and  therefore
study visits in this analysis were allocated to week 60,
72, 84 and 96 (all +/-4 weeks).  The following data
were recorded at these visits if available in the patient
chart:  Cd4+  cell  count,  HIv-Rna  viral  load,  and
haematology and biochemistry laboratory results (in-
cluding liver enzymes and fasting lipids) as well as in-
formation  about  concomitant  lipid  lowering  agents
and other concomitant medication. Related clinical ad-
verse  events  and  treatment  adherence  information
were collected.  
EndPoInTS
Efficacy endpoints were: percentage of patients with
HIv-Rna<50 copies/ml at week 96; percentage of
patients with HIv-Rna<400 copies/ml at week 96;
changes in Cd4 cell count from baseline to week 96.
Safety and tolerability endpoints were: changes in fast-
ing  lipids  levels  (total  cholesterol  [TC],  high-density
lipoprotein [Hdl] and low-density lipoprotein [ldl]
cholesterol, and triglycerides) from baseline to one line
week 96 stratified according to baseline levels; changes
in liver enzymes (alanine aminotransferase [alT], as-
partame aminotransferase [aST], and gamma glutamyl
transferase [ggT]) and bilirubin levels; frequency of
grade 3 and 4 adverse events or death considered to
be related to Sqv. 
STaTISTICS
all PI-na￯ve patients with complete baseline visit who
completed the initial 48 week analysis and who were
then treated with an Sqv/r-containing regimen for a
further 48 weeks (total 96 weeks) were included in the
analysis.  Efficacy  parameters  were  assessed  using  an
intent-to-treat (ITT) analysis (where missing data were
included as failure) and also, to reflect the observa-
tional nature of the study, a last observation carried
forward (loCF) analysis (where missing values were
taken as the previous observed value).  For evaluation
of safety parameters loCF analysis was used.
descriptive summary statistics were used for this
cohort  analysis,  describing  changes  in  Cd4+  cell
count and HIv-Rna from baseline, the type and fre-
quency of adverse events observed, and changes in
safety relevant laboratory parameters. For continuous
variables  the  following  statistics  were  calculated:
mean; standard deviation, median, inter-quartile range
(IqR) and minimum and maximum values. For cate-
gorical variables number of values in each category
and percentage of the values in regard to number of
patients in the study population were calculated. Ex-
plorative statistical methods were used with regard to
the efficacy endpoints and changes in safety-relevant
laboratory  parameters.  Changes  from  baseline  were
tested for significance using the wilcoxon signed rank
test. Shifts in ranking of baseline values and week 96
values  were  assessed  using  Shift  tables  and  Mcne-
mar/bowker tests.
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The initial 48 week analysis included 454 patients (275
aRT-na￯ve and 179 pretreated but PI-na￯ve). of these,
93 patients withdrew from treatment prior to the end
of the 48 week study and 77 patients had no available
data after week 48; these 170 patients were excluded
from the 96 week analysis. The remaining 284 patients
consisted of 175 aRT-na￯ve and 109 pretreated but
PI-na￯ve individuals. 
baseline  characteristics  and  demographics  are
shown in Table 1. 
The  majority  of  patients  in  the  total  cohort  was
male  (83.1%)  and  Caucasian  (82.0%),  and  had  con-
tracted  HIv  infection  through  MSM  risk  behavior
(59.9%).  Median  HIv  Rna  levels  were  lower  and
Cd4  levels  higher  in  pretreated  patients  compared
with  aRT-na￯ve  patients.  around  one  third  of  pre-
treated patients had an interruption in treatment prior
to  beginning  Sqv/r,  with  a  median  duration  of  2
years. of the pretreated but PI-na￯ve patients, 43.1%
had  previous  virological  failure  with  nRTI/nnRTI
therapy,  and  20.2%  had  previous  toxicity  (72.7%  of
these to nnRTIs)
details  of  other  antiretroviral  drugs  used  with
Sqv/r in this analysis are shown in Table 2.
The  most  commonly  used  treatment  regimen  in
aRT-na￯ve  patients  and  pretreated  but  PI-na￯ve  pa-
tients  was  Sqv/r  in  combination  with  two  nRTIs,
predominantly  tenofovir  and  emtricitabine.  around
one third of pretreated but PI-na￯ve patients received
Sqv/r  as  double  PI  therapy,  predominantly  with
lopinavir.
dISConTInuaTIonS FRoM wEEk 48 To wEEk 96
In the aRT-na￯ve group, a total of 31 patients (17.7%)
were  recorded  as  having  withdrawn  from  the  study
prematurely.  The  main  reasons  for  premature  with-
drawal from treatment were (percentages are based on
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Table 1. baseline Characteristics and demographics.
ART-na￯ve patients Pretreated, but PI-na￯ve patients
(n = 175) (n = 109)
Male (n) 86 % (n = 150) 79 % (n = 86)
Age in years, Median (IQR) 39 (33; 46) 41 (37; 50)
Height in cm, Median, (IQR) 176 (172; 183) 178 (170; 182)
Weight in kg, Median (IQR) 72 (65; 79) 72 (65; 80)
Hepatitis B coinfection 5 % (n = 9) 2 % (n = 2)
Hepatitis C coinfection 12 % (n = 21) 10 % (n = 11)
Infection mode
MSM 61 % 59 %
Heterosexual 19 % 17 %
IVDU 6 % 6 %
Not specified 14 % 18 %
Race
Caucasian 85 % 78 %
African 8 % 11 %
Asian 3 % 5 %
Not specified 4 % 6 %
CDC stage
A 38 % 29 %
B 33 % 51 %
C 27 % 17 %
Not specified 2 % 3 %
Time since first diagnosis in years, Median (IQR) 1 (0; 4) 9 (5; 13)
Time since first ART in months, Median (IQR) - 79 (37; 104)
Number of previous regimen, Median (IQR) - 3 (2; 4)
Treatment interruption before start of new regimen - 28 % (n = 30)
Duration of treatment interruption in months, Median (IQR) - 24 (6; 40)
HIV RNA (copies/mL), Median (IQR) 117,000 3,433
(36,548; 336,000) (92; 34,384)
CD4-count (cells/mmﾳ) Median (IQR) 196 (82; 284) 319 (204; 478)
IqR: Inter quartile range; MSM: Men who have sex with men; CdC: Center for disease Control; aRT: antiretroviral therapy;
nRTIs: nucleoside reverse transcription inhibitors; PI: Protease inhibitor; Ivdu: Intravenous drug use
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to follow-up (n = 8; 25.8%), side effects
(n = 7; 22.6%) and virologic failure (n =
4; 12.9%). other reasons were reported in
11 patients (35.5%). no reason for pre-
mature  withdrawal  was  provided  in  one
(3.2%) case. In the pretreated but PI-na￯ve
group, 12 patients (11.0%) were recorded
as having withdrawn from the study pre-
maturely. The main reasons for premature
withdrawal from treatment were (percent-
ages are based on number of premature
withdrawals):  adherence  issues  (n  =  4;
33.3%), lost to follow-up (n = 2; 16.7%)
and virologic failure (n = 2; 16.7%). other
reasons  were  reported  in  three  patients
(25.0%). no reason for premature with-
drawal was provided in one (8.3%) case.
EFFICaCy
The percentages of patients with HIv-1
Rna <50 copies/ml and <400 copies/
ml at baseline and at week 96 are shown
in  Figure  1.  a  larger  proportion  of  pa-
tients  who  were  pretreated  but  PI-na￯ve
had  HIv-1  Rna  <50  copies/ml  and
<400 copies/ml at baseline (22.0% and
27.5%, respectively) compared with those
patients who were aRT-na￯ve (0.6% and
2.9%, respectively. a similar proportion of
patients in the aRT-na￯ve and in the pre-
treated  but  PI-na￯ve  group  had  HIv-1
Rna levels <400 copies/ml (ITT analy-
sis: 68.0% and 70.6%, respectively; loCF
analysis: 96.6% and 90.8%, respectively).
The  proportion  of  patients  with  HIv
Rna <50 copies/ml was higher in the
aRT-na￯ve group compared with the pre-
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Table 2. antiretroviral drugs included in Sqv/r regimens.
ART-na￯ve Pretreated but PI-na￯ve
n% n%
2 NRTI 129 74 54 59.5
TDF/FTC 82 47 38 35
AZT/3TC 29 17 44
3TC/ABC 14 88 7
PI 19 11 30 27.5
LPV 19 11 20 18
ATV 06 5.5
FAP 04 4
PI + NRTI/NNRTI 53 87
LPV 25 4.5
ATV 23 2.5
FAP 1 02
Not specified 00 11
Other 22 12 16 15
nRTI: nucleoside reverse transcriptase inhibitor; nnRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor;
TdF: tenofovir; FTC: emtricitabine; aZT: zidovudine; 3TC: lamivudine; abC: abacavir; lPv: lopinavir; aTv: atazanavir; FaP:
fosamprenavir
Fig. 1. Proportion of a) aRT-na￯ve and b) pretreated but PI-na￯ve patients
with HIv-1 Rna <50 copies/ml and <400 copies/ml at baseline (bl) and
week 96 (w96).
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56.9%, respectively; loCF analysis: 84.0% and 75.2%,
respectively). Median change in HIv Rna levels from
baseline to week 96 was -3.35 log10 copies/ml (IqR
one line -3.79; -2.87) by ITT analysis and -3.33 log10
copies/ml (IqR -3.82; -2.84) by loCF analysis in the
aRT-na￯ve  group.  For  the  pretreated  but  PI-na￯ve
group, median change HIv Rna levels from baseline
to week 96 was -1.76 log10 copies/ml (IqR -2.61 one
line; -0.35) by ITT analysis and -1.66 log10 copies/ml
(IqR -2.60; -0.04) by loCF analysis.
Median Cd4 counts from baseline to week 96 in-
creased during treatment in both patient groups (Fig.
2). In the aRT-na￯ve group, by loCF analysis, median
change in Cd4 count was +263 cells/mm3 (IqR 170;
384) at week 96 from a baseline level of 196 (IqR 82;
284)  (p<0.0001).  Similar  results  were  seen  by  ITT
analysis  (median  change  +290  cells/mm3 [IqR  184;
398]) (p<0.0001). Median increase in Cd4 cell count
at week 96 was lower in the pretreated but PI-na￯ve
group at +181 cells/mm3 (IqR 60; 309; loCF analy-
sis), but this group had higher initial baseline levels
(319 [IqR 204; 478]). The change in Cd4 cell count
from  baseline  to  week  96  remained  significant
(p<0.0001; loCF analysis). Similar results were seen
by ITT analysis (median change +203 cells/mm3 [IqR
90; 325]) (p<0.0001).
SaFETy and TolERabIlITy
Treatment with Sqv/r was well tolerated and no un-
expected adverse events (aE) were reported between
week 48 and week 96. In the aRT-na￯ve group, there
were 10 (5.7%) patients who experienced at least one
aE during the course of the study (each reported one
aE). Two aEs in 2 patients (1.1%) were considered as
related  of  study  drug  (nausea  and  diarrhoea,  both
grade 2). There were four aEs in four patients (2.3%)
with grade 3 or 4 intensity (hypertonia, iron deficien-
cy anaemia, syphilis, and delusional depression) none
of which were considered to be related to Sqv. In the
treatment  experienced  but  PI-na￯ve  group,  one  aE
was reported in one patient (0.9%) during the course
of  the  study.  The  aE  (skin  eruption  to  face)  was
grade 3 intensity and was considered to probably be
related  to  Sqv.  The  aE  resolved  without  sequelae.
no deaths were reported during the extended treat-
ment period.
In aRT-na￯ve patients, median changes in liver en-
zymes  from  baseline  at  week  96  for  male  patients
were: alT -4.9 u/l (IqR one line -23.0; 4.0); aST -
2.7 (IqR one line -12.0; 4.0); ggT -1.3 (IqR -18.5;
7.0) (loCF). For female patients median changes in
liver enzymes from baseline at week 96 were: alT -1.0
u/l (IqR -6.0; 10.0); aST -2.0 (IqR -7.7; 4.0); ggT
5.0 (IqR -16.0; 11.0) (loCF). overall median change
in bilirubin level from baseline at week 96 was +0.1
mg/dl (IqR -0.08, 0.29) (loCF). In all, one of 165
patients  with  normal  levels  at  baseline  had  a  grade
3/4 increase in alT and three of 132 patients with
normal levels at baseline had a grade 3/4 increase in
aST at week 96. normalization of liver enzymes at 96
weeks occurred in around half of patients who had
pre-existing abnormal (grade 3/4) levels (alT 3 out
of 6 patients; aST 3 out of 5 patients; ggT 3 out of
6 patients).
In pretreated but PI-na￯ve patients, median changes
in liver enzymes from baseline at week 96 for male pa-
tients were: alT -1.0 u/l (IqR -15.0; 7.0); aST -1.0
(IqR -12.0; 6.0); ggT -4.5 (IqR -21.5; 9.0) (loCF).
For female patients median changes from baseline at
week 96 were: alT -2.0 u/l (IqR -12.0; 5.0); aST
0.0 (IqR -9.5; 8.5); ggT 0.0 (IqR -8.0; 16.0) (loCF).
overall median change in bilirubin level from baseline
at  week  48  was  +0.1  mg/dl  (IqR  -0.16;  0.30)
(loCF). In all, one of 82 patients with normal levels
at baseline had a grade 3/4 increase in alT and one
of  75  patients  with  normal  levels  at  baseline  had  a
grade 3/4 increase in aST at week 96. normalization
of liver enzymes at 96 weeks occurred in 2 out of 3
patients who had pre-existing abnormal (grade 3/4)
levels of alT at baseline and 3 out of 6 patients who
had pre-existing abnormal (grade 3/4) levels of ggT
at baseline.
as this was an observational study, details of dose
reductions due to adverse events were not available. 
CHangES In lIPId PRoFIlES
Median changes in fasting TC, triglyceride, ldl and
Hdl levels from baseline to week 96 for the two pa-
tient groups are shown in Figures 3a and 3b. 
In the aRT-na￯ve group, the majority of patients
had TC levels < 200 mg/dl and triglyceride levels <
200 mg/dl at baseline and week 96 (81.8% and 75.2%
at baseline and 50.7% and 62.4% at week 96, respec-
tively). when stratified by baseline levels, there was a
significant  shift  towards  an  increase  in  TC  levels
(p<0.0001; Mcnemar/bowker test) and a in triglyc-
eride levels (p = 0.05; Mcnemar/bowker test). In all,
one of 148 patients with normal levels at baseline had
a grade 3/4 increase in TC and one of 149 patients
EuRoPEan JouRnal oF MEdICal RESEaRCH March 28, 2011 97
Fig. 2. Change of Cd4 cell count (me-
dian ﾱ IqR) from baseline to week 96
(loCF).
1) Knechten_Umbruchvorlage  14.03.11  11:52  Seite 97with  normal  levels  at  baseline  had  a  grade  3/4  in-
crease  in  triglyceride  levels  at  week  96.  Increases  in
median TC and triglyceride levels tended to occur in
the initial weeks of treatment with more stable levels
in later weeks (Figs. 4a and 4b).
In  the  pretreated  but  PI-na￯ve  group,  75.9%  and
54.2% of patients had TC levels < 200 mg/dl at base-
line and 96 weeks, respectively, and 67.1% and 59.8%
of  patients  had  triglyceride  levels  <200  mg/dl  at
baseline and week 96, respectively. when stratified by
baseline levels, there was a shift towards an increase in
TC levels (p = 0.001; Mcnemar/bowker test); there
was  no  significant  shift  in  triglyceride  levels  (p  =
0.105; Mcnemar/bowker test). In all, two of 63 pa-
tients with normal levels at baseline had a grade 3/4
increase in TC at week 96. Increases in median TC and
triglyceride levels tended to occur in the initial weeks
of  treatment  with  more  stable  levels  in  later  weeks
(Fig. 4a and 4b).
by  week  96  the  proportion  of  patients  receiving
lipid lowering agents increased from 0.6% at baseline
to 2.9% in aRT-na￯ve patients and from 1.8% to 9.2%
in pretreated but PI-na￯ve patients.
dISCuSSIon
This  analysis  demonstrates  that  long-term  treatment
with Sqv/r is effective and well-tolerated both as first
line  therapy  in  aRT-na￯ve  patients  and  in  pretreated
but PI-na￯ve patients treated in real-life clinical settings. 
The efficacy of Sqv/r 1000/100 mg bid in treat-
ment-na￯ve patients using the 500 mg film-coated for-
mulation of Sqv up to 48 weeks has been reported
previously in the clinical trial setting [8], and confirmed
by similar findings in our 48 week analysis of patients
treated in routine clinical practice in the RaInbow
cohort [10]. The 96 week data presented here extend
and support evidence of efficacy and safety of Sqv/r
in ‘real world’ settings. all efficacy parameters in the
current study had increased at 96 weeks relative to the
previously reported 48 week data [10]. as the current
analysis included only a subset of patients from the ini-
tial  48  week  cohort,  we  also  compared  the  96  week
data with 48 week data from this subset only to con-
firm our findings. all efficacy parameters were found
to have increased at 96 weeks by loCF analysis, al-
though the proportion of patients with HIv Rna <50
and  <400  copies/ml  at  week  96  was  slightly  lower
than at week 48, reflecting the fact that data were miss-
ing at this timepoint for around a quarter of patients in
both groups, compared with only around 8% missing
data at week 48 (data no shown). our findings are con-
sistent with those reported by ananworanich and col-
leagues in a long-term study of 272 aRT-na￯ve Thai
patients treated with Sqv/r plus two nRTIs [7], which
showed that one line response in terms of HIv viral
load and Cd4 count at 48 weeks was maintained at 96
weeks of treatment. 
Changes in lipid profile are a characteristic of treat-
ment with PIs to a greater or lesser degree, and are of
particular  concern  given  the  possible  link  between
treatment-related  dyslipidemia  and  its  contribution  to
atherogenesis and increased risk of coronary artery dis-
ease  [12].  a  significant  shift  towards  increases  from
baseline in fasting total cholesterol were seen in both
groups of patients, but only one patient in the aRT-
na￯ve  group  and  two  in  the  pretreated  but  PI-na￯ve
group showed a grade 3/4 increase from normal base-
line levels. Increases were also seen in ldl cholesterol,
Hdl cholesterol and triglyceride. overall, median in-
creases in TC and triglycerides from baseline in the cur-
rent analysis are somewhat higher than those reported
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Fig.  3.  Median  change
(IqR) in lipid values from
baseline (bl) to week 96 in
a)  aRT-na￯ve  and  b)  pre-
treated  but  PI-na￯ve  pa-
tients  (loCF).  ldl:  low
density  lipoprotein;  Hdl:
high density lipoprotein.
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sis and the gEMInI study [8, 10], which might suggest
a general increase in lipid levels with time on treatment.
However, when changes were examined only in the co-
hort of patients treated for the full 96 weeks in the cur-
rent  analysis,  increases  were  largely  seen  in  the  early
stages of treatment and lipid levels remained relatively
stable in later weeks. The TC, triglyceride and ldl one
line levels at 96 weeks are somewhat higher in the cur-
rent study than those reported in a long-term study of
272 aRT-na￯ve Thai patients treated with Sqv/r plus
two nRTIs [7]. This may reflect the difference in race
between the study populations which has been shown
to affect Sqv pharmacokinetics [13, 14], differences in
body mass index in Thai compared with Caucasian pa-
tients, and differences in the combinations of antiretro-
virals  used,  which  makes  direct  comparison  between
the  studies  difficult.  overall,  the  incidence  of  grade
3/4 changes in lipid level following 96 weeks treatment
was low in the current analysis of the RaInbow Co-
HoRT, and at least 50% of patients remained within
the normal range. 
Treatment with Sqv/r was well tolerated up to one
line 96 weeks, with only seven patients in the total co-
hort (2.5%) withdrawing from treatment due to side ef-
fect issues, confirming the low incidence reported at 48
weeks [8, 10]. The incidence and nature of aEs were
similar in both aRT-na￯ve and pretreated but PI-na￯ve
patients, and were similar to those previously reported
(most commonly gastrointestinal and diarrhea). with
regard to laboratory values, there was no evidence of
relevant changes in liver enzymes or bilirubin in either
patient group, with the exception of two patients who
showed a grade 3/4 rise from within normal limits at
baseline  in  alT  (one  patient  from  each  group)  and
four patients with normal levels at baseline who had a
grade  3/4  increase  in  aST  (three  in  the  aRT-na￯ve
and one in the pretreated but aRT-na￯ve group).
The main strengths of the current analysis of pa-
tients from the RaInbow survey lies in the fact that
it consists of an unselected cohort of HIv-infected
patients treated under routine, ‘real-life’ conditions in
contrast  to  the  highly  selective  and  controlled  ran-
domised  trial  situation.  The  data  derived  from  such
cohorts may more closely reflect clinical practice than
results obtained from the optimized setting of clinical
studies. However the study has limitations associated
with observational analyses. It is not possible to rule
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Fig.  4.  Median  a)  total
cholesterol and b) triglyc-
eride levels over time on
treatment (loCF).
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tors were encouraged to report data from all eligible
patients at their site rather than reporting on a random
subset only. another potential bias of observational
studies where clinic visits are not mandatory is the po-
tential for missing data, and efficacy data at 96 weeks
were missing for a proportion of patients in our co-
hort.  we  have  therefore  presented  these  data  using
both ITT (missing = failure) and loCF analyses to al-
low an assessment of the overall efficacy, with each
method having particular merits and drawbacks in this
situation. Finally, a comparison group was not avail-
able to act as a study control.
In conclusion, 96 week data from the RaInbow
cohort extends shorter term data which confirm the
efficacy and tolerability of Sqv/r seen in clinical trials
and in the ‘real-world’ setting in both aRT-na￯ve and
pretreated but PI-na￯ve patients. data from the cur-
rent  study  demonstrate  that  antiviral  response  to
Sqv/r is durable, and that long-term treatment is well
tolerated in routine clinical management.
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